Lee S-G, Kim J, Oh M-S, Ryu B, Kang K-R, Baek J, Lee J-M, Choi S-O, Kim C-Y and Chung HM.
Biochemical and Biophysical Research Communications, 2021
Summary:
The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a cardiotoxicity screening paradigm which has been proposed to use iPSC-derived cardiomyoctye evaluation in electrophysiological technology. This safety pharmacology test would help to overcome limitations in current testing systems. Measuring cardiomyoctye contractile force (inotropy) is an important factor in non-proarrhythmic cardiotoxicity. Using Axion's Maestro multielectrode array (MEA) platform the authors measured the electrophysiological changes (including field potential) in hiPSC-derived CMs with six different drugs and confirmed that the recorded response matched the mechanism of the drugs.
